NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
Clinical Trials
85 trialsNCT04300647 2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2 Completed
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT04221945 2026-02-20
KEYNOTE-A18
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT04646005 2025-09-08
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT00092534 2025-08-01
FUTURE II
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03104699 2025-07-30
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus Inc.
Phase 1/2 Completed
NCT03444376 2025-07-30
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
Genexine, Inc.
Phase 1/2 Completed
NCT04693234 2025-04-27
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
BeiGene
Phase 2 Completed
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT05012397 2024-10-17
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Phase 2 Terminated
NCT01284348 2024-08-29
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT02164461 2024-05-20
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Phase 1 Completed
NCT03629886 2024-03-15
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
GlaxoSmithKline
Phase 4 Completed
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT04246489 2023-10-23
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
EMD Serono
Phase 2 Completed
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT01076400 2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT02988817 2023-08-01
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
Phase 1/2 Completed
NCT03438396 2023-07-25
A Trial of Tisotumab Vedotin in Cervical Cancer
Seagen Inc.
Phase 2 Completed
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT01234480 2023-05-16
Intended Use Study of the BD SurePath Plus™ Pap
Becton, Dickinson and Company
Terminated
NCT03073525 2023-04-05
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
Phase 2 Completed
NCT02291055 2023-03-20
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Advaxis, Inc.
Phase 1/2 Terminated
NCT03386721 2023-02-21
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 2 Terminated
NCT02025985 2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT00943722 2022-10-03
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT02001623 2021-12-29
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT03245736 2021-11-04
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen Inc.
Phase 2 Completed
NCT00900562 2021-10-28
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
PharmaMar
Phase 2 Terminated
NCT04099277 2021-08-31
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02552121 2021-04-08
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT02172911 2021-02-21
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT01851772 2021-01-12
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Xoft, Inc.
Phase NA Completed
NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT01381575 2020-06-09
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
GlaxoSmithKline
Phase 3 Completed
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00637195 2020-01-03
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
GlaxoSmithKline
Phase 3 Completed
NCT00294047 2020-01-02
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
GlaxoSmithKline
Phase 3 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed